We confirmed this by finding that anti-CXCR3 blocked the therapeutic effect bintrafusp alfa, resulting in tumor growth, survival, and a TME indistinguishable from nonresponders to bintrafusp alfa. The gene discussed is CXCR3; the disease is neoplasm.